These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
334 related articles for article (PubMed ID: 18260095)
21. The metabolic disposition of aprepitant, a substance P receptor antagonist, in rats and dogs. Huskey SE; Dean BJ; Doss GA; Wang Z; Hop CE; Anari R; Finke PE; Robichaud AJ; Zhang M; Wang B; Strauss JR; Cunningham PK; Feeney WP; Franklin RB; Baillie TA; Chiu SH Drug Metab Dispos; 2004 Feb; 32(2):246-58. PubMed ID: 14744948 [TBL] [Abstract][Full Text] [Related]
23. Absorption, distribution, metabolism, and excretion of dirlotapide in the dog. Merritt DA; Bessire AJ; Vaz AD; Sams JP; Lynch MP J Vet Pharmacol Ther; 2007 Aug; 30 Suppl 1():17-23. PubMed ID: 17567511 [TBL] [Abstract][Full Text] [Related]
24. Characterization of the pharmacokinetics of dioscin in rat. Li K; Tang Y; Fawcett JP; Gu J; Zhong D Steroids; 2005 Jul; 70(8):525-30. PubMed ID: 15894036 [TBL] [Abstract][Full Text] [Related]
25. Assessing the plasma pharmacokinetics, tissue distribution, excretion and effects on cholesterol pharmacokinetics of a novel hydrophilic compound, FM-VP4, following administration to rats. Wasan KM; Peteherych KD; Najafi S; Zamfir C; Pritchard PH J Pharm Pharm Sci; 2001; 4(3):207-16. PubMed ID: 11737986 [TBL] [Abstract][Full Text] [Related]
26. Metabolism and excretion of trovafloxacin, a new quinolone antibiotic, in Sprague-Dawley rats and beagle dogs. Effect of bile duct cannulation on excretion pathways. Dalvie DK; Khosla NB; Navetta KA; Brighty KE Drug Metab Dispos; 1996 Nov; 24(11):1231-40. PubMed ID: 8937858 [TBL] [Abstract][Full Text] [Related]
27. Tissue distribution and biotransformation of zopolrestat, an aldose reductase inhibitor, in rats. Schneider RP; Fouda HG; Inskeep PB Drug Metab Dispos; 1998 Nov; 26(11):1149-59. PubMed ID: 9806959 [TBL] [Abstract][Full Text] [Related]
28. Disposition of the dipeptidyl peptidase 4 inhibitor sitagliptin in rats and dogs. Beconi MG; Reed JR; Teffera Y; Xia YQ; Kochansky CJ; Liu DQ; Xu S; Elmore CS; Ciccotto S; Hora DF; Stearns RA; Vincent SH Drug Metab Dispos; 2007 Apr; 35(4):525-32. PubMed ID: 17220241 [TBL] [Abstract][Full Text] [Related]
29. Metabolism, disposition, excretion, and pharmacokinetics of levormeloxifene, a selective estrogen receptor modulator, in the rat. Mountfield RJ; Kiehr B; John BA Drug Metab Dispos; 2000 May; 28(5):503-13. PubMed ID: 10772628 [TBL] [Abstract][Full Text] [Related]
30. Absorption and enterohepatic circulation of baicalin in rats. Xing J; Chen X; Zhong D Life Sci; 2005 Nov; 78(2):140-6. PubMed ID: 16107266 [TBL] [Abstract][Full Text] [Related]
31. Kinetics and disposition of hexarelin, a peptidic growth hormone secretagogue, in rats. Roumi M; Marleau S; du Souich P; Maggi T; Deghenghi R; Ong H Drug Metab Dispos; 2000 Jan; 28(1):44-50. PubMed ID: 10611139 [TBL] [Abstract][Full Text] [Related]
32. Biodisposition studies with the acyl-coenzyme A: cholesterol acyltransferase inhibitor 2,2-dimethyl-N-(2,4,6-trimethoxyphenyl)dodecanamide, CI-976. Woolf TF; Black A; Shum YY; McNally W; Lee H; Chang T Drug Metab Dispos; 1993; 21(6):1112-8. PubMed ID: 7905392 [TBL] [Abstract][Full Text] [Related]
33. Metabolism, excretion, and pharmacokinetics of (3-{[4-tert-butyl-benzyl)-(pyridine-3-sulfonyl)-amino]-methyl}-phenoxy)-acetic acid, an EP2 receptor-selective prostaglandin E2 agonist, in male and female Sprague-Dawley rats. Johnson KA; Prakash C Drug Metab Dispos; 2005 Aug; 33(8):1191-201. PubMed ID: 15886349 [TBL] [Abstract][Full Text] [Related]
34. Pharmacokinetics, biliary excretion, and tissue distribution of novel anti-HIV agents, cosalane and dihydrocosalane, in Sprague-Dawley rats. Kuchimanchi KR; Udata C; Johnston TP; Mitra AK Drug Metab Dispos; 2000 Apr; 28(4):403-8. PubMed ID: 10725308 [TBL] [Abstract][Full Text] [Related]
35. Biliary excretion and enterohepatic recirculation of morphine-3-glucuronide in rats. Ouellet DM; Pollack GM Drug Metab Dispos; 1995 Apr; 23(4):478-84. PubMed ID: 7600915 [TBL] [Abstract][Full Text] [Related]
36. Toxicokinetics and biotransformation of 3-(4-methylbenzylidene)camphor in rats after oral administration. Völkel W; Colnot T; Schauer UM; Broschard TH; Dekant W Toxicol Appl Pharmacol; 2006 Oct; 216(2):331-8. PubMed ID: 16806338 [TBL] [Abstract][Full Text] [Related]
37. In vivo metabolism of [14C]ruboxistaurin in dogs, mice, and rats following oral administration and the structure determination of its metabolites by liquid chromatography/mass spectrometry and NMR spectroscopy. Barbuch RJ; Campanale K; Hadden CE; Zmijewski M; Yi P; O'Bannon DD; Burkey JL; Kulanthaivel P Drug Metab Dispos; 2006 Feb; 34(2):213-24. PubMed ID: 16258078 [TBL] [Abstract][Full Text] [Related]
38. Pharmacokinetics, tissue distribution, and excretion of buagafuran in rats. Hu JP; Wang WJ; Chen H; Li YW; Fan JH; Li Y J Asian Nat Prod Res; 2011 Mar; 13(3):205-14. PubMed ID: 21409681 [TBL] [Abstract][Full Text] [Related]
39. Biotransformation of carbon-14-labeled muraglitazar in male mice: interspecies difference in metabolic pathways leading to unique metabolites. Li W; Zhang D; Wang L; Zhang H; Cheng PT; Zhang D; Everett DW; Humphreys WG Drug Metab Dispos; 2006 May; 34(5):807-20. PubMed ID: 16467134 [TBL] [Abstract][Full Text] [Related]
40. Absorption, distribution, metabolism and excretion of YM466, a novel factor Xa inhibitor, in rats. Mano Y; Sonoda T; Nakamura E; Usui T; Kamimura H Biopharm Drug Dispos; 2004 Sep; 25(6):253-60. PubMed ID: 15334624 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]